Screener / SEC EDGAR /CIK 0001388658 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Instruments

iRhythm Holdings, Inc. IRTC

iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. 10-K, Item 1

Employees
2,400
Headquarters
San Francisco, CA
CEO
Quentin S. Blackford
Next results
around Feb 18, 2027
Compare with peers Embed

IRTC among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 26.2%, above 80% of 154 peers (their median 10.4%) REVENUE GROWTH 26.2% · above 80% Gross margin: 72.3%, above 75% of 107 peers (their median 63.4%) GROSS MARGIN 72.3% · above 75% Operating margin: -5.7%, above 22% of 138 peers (their median 10.2%) OPERATING MARGIN -5.7% · above 22% Net margin: -4.5%, above 24% of 153 peers (their median 6.8%) NET MARGIN -4.5% · above 24% FCF margin: 0.9%, above 20% of 144 peers (their median 10.1%) FCF MARGIN 0.9% · above 20%
IRTC Peer median Below the median

What changed

10 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 19, 2026 against Feb 20, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Inventory growing faster than revenue
    Inventory +54.1% ($14.0M to $21.6M) vs revenue +26.2% ($591.8M to $747.1M), +27.9 pts apart
  • Auditor change
    8-K item 4.01 (change in certifying accountant) filed Apr 1, 2026
  • Receivables -5.3% ($79.9M to $75.7M) vs revenue +26.2% ($591.8M to $747.1M), -31.5 pts apart
8 more checks with nothing to note
  • Cash from operations $80.9M vs net income −$44.6M (FY ending Dec 31, 2025)
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Contractual Allowance - Contracted Third-Party Payors
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

10 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.

All 10 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    We also regularly evaluate a variety of other potential strategic transactions, including equity and other investments and strategic alliances. Equity and other investments and strategic alliances pose additional risks, as we could share ownership and, in some cases, management responsibilities with one or more other parties whose…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Healthcare laws and regulations, and interpretations of the same, change frequently and may change significantly in the future. We may not be able to adapt our operations to address every new regulation or interpretation, and new regulations or interpretations may adversely affect our business. For example, FDA has taken novel steps in…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    As a public company, we are subject to certain reporting requirements, including those under the Sarbanes-Oxley Act, which requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In order to maintain and improve the effectiveness of our internal controls…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    In addition, the BIOSECURE Act was signed into law in December 2025 as part of the National Defense Authorization Act restricting U.S. federal contracts and funding for companies using biotech equipment or services from "biotechnology companies of concern" ("BCCs"), to curb national security risks. A phased rollout includes publishing…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$410.9M$492.7M$591.8M$747.1M
Net income−$116.2M−$123.4M−$113.3M−$44.6M
Operating cash flow−$23.0M−$50.1M$3.4M$80.9M
Free cash flow−$52.8M−$90.5M−$30.6M$34.5M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$747.1M ▲ 26.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

iRhythm Holdings, Inc., San Francisco, CA · from the 10-K filed Feb 19, 2026

iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.

Headquarters
San Francisco, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026

Employees, at the top of the page: "As of December 31, 2025, we had approximately 2,400 employees globally" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IRTC/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.